Used as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6, this compound plays a key role in cancer research. It interferes with the cell cycle progression in tumor cells by blocking the G1 to S phase transition, leading to cell cycle arrest and inhibition of proliferation. It is widely applied in studies targeting breast cancer, leukemia, and other malignancies where CDK dysregulation is involved. Due to its ability to cross the blood-brain barrier, it is also explored in models of central nervous system tumors. Its selectivity makes it a valuable tool for developing targeted therapies with reduced off-target effects.